Coherus Oncology, Inc. cotiza a 1.03 USD y tiene una capitalización bursátil de $159M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 i…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.19 | $-0.25 | $-0.34 |
| Estimado | $-0.21 | $-0.11 | $-0.26 | $-0.33 |
| Sorpresa | — | -72.7% | +3.8% | -3.0% |
| Métrica | CHRS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 67.2% | 57.0% | +10.2% |
| Operating Margin | -429.5% | -38.6% | -390.9% |
| Net Margin | 398.4% | -33.6% | +432.0% |
| FCF Margin | — | -13.9% | — |
| ROE | 275.4% | -40.4% | +315.8% |
| ROA | 65.0% | -32.0% | +97.1% |
| Current Ratio | 1.47 | 2.84 | -1.37 |
| Debt / Equity | — | 0.28 | — |